[ELITE PHARMACEUTICALS LOGO]

             ELITE PHARMACEUTICALS APPOINTS CHIEF SCIENTIFIC OFFICER

NORTHVALE, N.J.--February 14, 2007--Elite Pharmaceuticals,  Inc. ("Elite" or the
"Company")  (AMEX:  ELI),  announced the  appointment of Veerappan  Subramanian,
Ph.D. as its acting Chief Scientific Officer.

Dr.  Subramanian  has been  responsible  for the development and FDA approval of
over  150  specialty  and  generic  drug  products  during  his 33  years in the
pharmaceutical  industry. He was the founder and Chief Executive Officer of Kali
Laboratories,  Inc.,  a  specialty  generic  pharmaceutical  company,  which was
acquired by Par Pharmaceuticals in 2004. Currently,  Dr. Subramanian heads Novel
Laboratories Inc., a specialty  pharmaceutical company focusing on the research,
development,  manufacturing,  licensing  and  acquisition  of specialty  generic
pharmaceuticals, of which Elite owns 49% of the outstanding equity.

In his capacity as acting Chief Scientific Officer, Dr. Subramanian will oversee
all scientific activities and personnel of the Company.

"We  are  fortunate  to  have  such a  skilled  and  experienced  pharmaceutical
developer and executive leading our scientific  activities as we enter the later
stages of clinical testing of our pain products. Dr. Subramanian's experience in
the  development  and  commercialization  of  pharmaceutical  products  and  his
outstanding  scientific and  regulatory  expertise will be invaluable in driving
our growth strategy and creating value for our shareholders." said Bernard Berk,
Chairman and CEO of Elite.

Dr. Charan Behl, the former Chief Scientific Officer of the Company, will assume
the position of Head of  Technical  Affairs and oversee the  Company's  clinical
programs,  process development,  analytical development and quality control with
respect to the Company's products. On February 9, 2007, the Company and Dr. Behl
entered into an amended employment agreement.

ABOUT ELITE PHARMACEUTICALS

Elite Pharmaceuticals is a specialty  pharmaceutical company principally engaged
in the development and manufacturing of oral  controlled-release  products.  The
Company's  strategy includes  developing  generic versions of controlled release
drug products with high barriers to entry and assisting partner companies in the
life cycle management of products to improve  off-patent drug products.  Elite's
technology  is  applicable  to develop  delayed,  sustained or targeted  release
capsules or tablets. Elite has one product currently being sold commercially and
a pipeline of eight other drug products  under  development  in the  therapeutic
areas that include pain management,  allergy,  cardiovascular and infection. The
addressable  market for Elite's  current  pipeline  of generic and branded  drug
products  exceeds $6 billion.  Elite also has a GMP and DEA registered  facility
for research, development, and manufacturing located in Northvale, NJ.

THIS NEWS RELEASE CONTAINS FORWARD-LOOKING  STATEMENTS,  INCLUDING THOSE RELATED
TO THE PRELIMINARY  NATURE OF THE CLINICAL PROGRAM RESULTS AND THE POTENTIAL FOR
FURTHER  PRODUCT  DEVELOPMENT,  THAT INVOLVE  KNOWN AND UNKNOWN  RISKS,  DELAYS,
UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE CONTROL OF ELITE,  WHICH MAY CAUSE
ACTUAL RESULTS, PERFORMANCE






OR  ACHIEVEMENTS  OF THE COMPANIES TO BE MATERIALLY  DIFFERENT FROM THE RESULTS,
PERFORMANCE OR OTHER EXPECTATIONS IMPLIED BY THESE  FORWARD-LOOKING  STATEMENTS.
IN  PARTICULAR,  BECAUSE  SUBSTANTIAL  FUTURE  TESTING WILL BE REQUIRED PRIOR TO
APPROVAL, THE RESULTS DESCRIBED ABOVE MAY NOT BE SUPPORTED BY ADDITIONAL DATA OR
BY THE RESULTS OF SUBSEQUENT  TRIALS.  THESE RISKS AND OTHER FACTORS,  INCLUDING
THE TIMING OR RESULTS OF PENDING AND FUTURE CLINICAL TRIALS,  REGULATORY REVIEWS
AND  APPROVALS  BY  THE  FOOD  AND  DRUG  ADMINISTRATION  AND  OTHER  REGULATORY
AUTHORITIES,  AND INTELLECTUAL PROPERTY PROTECTIONS AND DEFENSES,  ARE DISCUSSED
IN THE ELITE'S  FILINGS WITH THE SECURITIES AND EXCHANGE  COMMISSION SUCH AS THE
10K, 10Q AND 8K REPORTS.  THE COMPANY  UNDERTAKES  NO  OBLIGATION  TO UPDATE ANY
FORWARD-LOOKING STATEMENTS.

FOR FURTHER INFORMATION, CONTACT:

Investor Relations
The Investor Relations Group
Dian Griesel/ Jordan Silverstein
Phone: 212-825-3210

For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
Phone: 518-398-6222
E-Mail: dwill@willstar.net
Website: WWW.ELITEPHARMA.COM